Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Zero Based Budgeting rests on allocating funds from zero, ensuring justification for every expense and alignment with priorities.
16,048 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
A major investor stepped into Crocs with a sizable new stake, valuing the position at about $53.7 million even as CRO...
A top hedge fund stepping up its Duolingo stake highlights conviction in the language-learning platform. This article...
Micron just beat earnings, but the stock didn’t soar. This article breaks down what happened, how AI demand, margins,...
A director sold a sizable chunk of World Kinect Corporation stock after a robust Q1.Is it a red flag or routine profi...
Genius Sports reported a significant top-line gain, with revenue up sharply last quarter. But a prominent investor ch...
When a company’s CFO reports a large stock sale, investors want to know what it implies. This article breaks down the...
When a CEO sells 38,000 Innodata shares, investors often wonder if the move signals trouble or simply a personal liqu...
When a long-time investor dumps a big stake, questions follow. This guide breaks down what an insider sale means for ...
OpenAI reportedly considers delaying its IPO, placing AI stocks in the spotlight. This guide breaks down the potentia...
Lovesac’s Q1 2027 narrative offers clues about demand, margins, and strategy for the year ahead. This article breaks ...
A large block sale can shake a stock, but it isn’t a crush course in risk. This guide explains what investors should ...